“Analysis”的搜索结果，显示 841-850 项，共有 2828 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the safety of a specific treatment regimen (protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN)) combined with ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and cyclophosphamide (VAC) followed by vinorelbine and ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Jacksonville, Fla. This is a prospective, pilot, single arm study to evaluate the incidence of IIC in patients with solid malignancies receiving VSL#3 and ICIs.

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This is a randomized Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...